Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial
Lisata will use Haystack’s minimal residual disease (MRD) test to evaluate the efficacy of certepetide at multiple points during a Phase II trial.
Diagnostics
NHS look to roll out HPV self-testing kits after YouSeek trial
Hyperfine’s portable MRI shows promise in stroke detection
Geneoscopy’s ColoSense deemed reliable in published study
Corundum backs study to develop algorithm for diagnosing dementia
Menarini’s non-invasive foetal test can detect foetal abnormalities
Intelligent Bio begins dosing for non-invasive drug screening technology
Sherlock starts clinical trial for rapid OTC diagnostics for STIs
